These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Non-selectivity of ERG reductions in eyes treated for retinoblastoma. Liu CY; Jonna G; Francis JH; Marr BP; Abramson DH; Brodie SE Doc Ophthalmol; 2014 Feb; 128(1):13-23. PubMed ID: 24213436 [TBL] [Abstract][Full Text] [Related]
7. Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. Abdelhakim AH; Francis JH; Marr BP; Gobin YP; Abramson DH; Brodie SE Br J Ophthalmol; 2017 May; 101(5):623-628. PubMed ID: 27539090 [TBL] [Abstract][Full Text] [Related]
8. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859 [TBL] [Abstract][Full Text] [Related]
9. Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision. Tsimpida M; Thompson DA; Liasis A; Smith V; Kingston JE; Sagoo MS; Reddy MA Br J Ophthalmol; 2013 Nov; 97(11):1464-70. PubMed ID: 24037611 [TBL] [Abstract][Full Text] [Related]
10. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Reddy MA; Naeem Z; Duncan C; Robertson F; Herod J; Rennie A; Liasis A; Thompson DA; Sagoo M Br J Ophthalmol; 2017 Dec; 101(12):1704-1708. PubMed ID: 28432112 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Francis JH; Abramson DH; Gobin YP; Marr BP; Tendler I; Brodie SE; Dunkel IJ Ophthalmology; 2015 May; 122(5):1016-22. PubMed ID: 25616769 [TBL] [Abstract][Full Text] [Related]
13. Chemosurgery for retinoblastoma: what we know after 5 years. Abramson DH Arch Ophthalmol; 2011 Nov; 129(11):1492-4. PubMed ID: 22084221 [No Abstract] [Full Text] [Related]
14. Preclinical Acute Ocular Safety Study of Combined Intravitreal Carboplatin and Etoposide Phosphate for Retinoblastoma. Mohney BG; Elner VM; Smith AB; Harbour JW; Smith BD; Musch DC; Smith SJ Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):151-159. PubMed ID: 28195618 [TBL] [Abstract][Full Text] [Related]
16. Complete regression of retinoblastoma following intra-arterial chemotherapy. Ni N; Shields CL; Bianciotto CG; Jabbour PM; Rosenwasser RH; Shields JA J Pediatr Ophthalmol Strabismus; 2011 Jun; 48 Online():e23-5. PubMed ID: 21634361 [TBL] [Abstract][Full Text] [Related]
17. Retinal vascular precipitates during administration of melphalan into the ophthalmic artery. Superstein R; Lederer D; Dubois J; Hamel P; Carret AS; Callejo S JAMA Ophthalmol; 2013 Jul; 131(7):963-5. PubMed ID: 23846208 [No Abstract] [Full Text] [Related]
18. Electroretinographic changes in the inner and outer retinal layers before and after intravenous chemotherapy for retinoblastoma. Kannan K; Jethva D; Parameswarappa DC; Kaliki S; Raval V Indian J Ophthalmol; 2024 Aug; 72(8):1168-1174. PubMed ID: 39078961 [TBL] [Abstract][Full Text] [Related]
19. Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Shields CL; Shields JA Clin Exp Ophthalmol; 2010 Aug; 38(6):638-43. PubMed ID: 20584015 [TBL] [Abstract][Full Text] [Related]